Project Grant R16NS147985
Award Date 8/7/25
Completion Date 7/31/29
Dollars Obligated $124K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- This federal Project Grant award for $528,876, provided by the National Institute on Aging (CFDA 93.866 Aging Research), supports research to investigate the cis- and trans-genetic regulation of brain transcriptomics and proteomics associated with Alzheimer's disease (AD) and AD-related dementias (ADRD). The key goals of the project are to: Estimate genome-wide cis- and trans-acting quantitative trait loci (QTLs) effects for transcriptome-wide genes and proteome-wide proteins across 4 brain...
- This federal Project Grant award of $839,933 from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research to investigate the role of N6-methyladenosine (m6A) RNA modifications in microglial dysfunction and Alzheimer's disease (AD) pathogenesis. The project aims to systematically map m6A modification landscapes in microglia isolated from human brain tissue and human induced pluripotent stem cell-derived microglial models. The researchers will also use CRISPR-based...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) will support a $185,074 research study conducted by the University of California, Berkeley. The goal of the study is to examine how brain network connectivity is associated with Alzheimer's disease (AD) risk, longitudinal pathology accumulation, and aging. The researchers will use positron emission tomography (PET) imaging and resting-state functional MRI (rs-fMRI) to investigate the mechanisms of how...
- This Project Grant award for $466,125, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), supports research to analyze the effects of Alzheimer's disease on subcellular transcriptome dynamics and mitonuclear coordination in neuronal soma and projections. The research, conducted by Harvard Medical School, will use a novel technique called Subcellular Timelapse-Seq (STL-Seq) to simultaneously quantify the kinetic rates of transcription, nuclear export, ribosome...
- This federal Project Grant award of $372,690, provided by the National Institute on Aging (CFDA 93.866 Aging Research), aims to comprehensively understand the heterogeneous causal pathophysiology of Alzheimer's disease (AD). The key objectives are to: (1) develop new statistical methods for uncovering heterogeneous causal relationships among amyloid-beta, tau accumulation, and cognition across diverse AD datasets; (2) apply these methods to reveal optimal treatment windows and target populations...
- This federal Project Grant award of $238,500 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research conducted by the University of California, San Diego (UCSD) to develop a new phosphorodiamidate morpholino oligonucleotide (PMO) therapeutic for treating Alzheimer's disease (AD). The research aims to create a highly effective PMO that can...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $781,008.00 to investigate the role of tRNA modifications in regulating mitochondrial function and the mitochondrial proteome in Alzheimer's disease and related disorders (AD/ADRD). The research aims to identify genetic mutations in mitochondrial DNA, tRNA genes, and genes encoding the mitochondrial proteome that are associated with AD status, using large-scale whole genome sequencing data from...
- This $500,000 Project Grant was awarded on September 15, 2024 by the National Institute on Aging (CFDA 93.866 Aging Research program) to Neucyte Inc., a minority-owned small business specializing in advanced biomedical research and development. The funding will support the development of a miniaturized "mini-brain" microphysiological system (MPS) platform using Alzheimer's disease (AD) patient-derived cells. The goal is to create a scalable, reproducible in vitro brain model that can...
- This $146,922 Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) supports research to investigate physiological pathways that modulate the regulation of the tau protein, which is associated with neurodegenerative diseases like Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). The research is being conducted by the Johns Hopkins University and aims to better understand how disruptions in the signaling pathway involving the enzyme GDE2 lead to...
- The federal Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), provides $426,674 to the University of North Carolina at Chapel Hill to investigate the "Implications of Long-Range Mossy Cell Signaling and Connectivity in Alzheimer's Disease (AD)". The 2-year project, starting on September 1, 2025, aims to identify changes in the activity of glutamatergic mossy cells in the dentate gyrus of the hippocampus and their impact on...